Turkish Journal of Medical Sciences




Aim: In this study, we aimed to assess the expression of CD117 in a large series of both Hodgkin´s and non-Hodgkin´s lymphoma, and to investigate the association between the expression patterns of CD117, IRF4/MUM1, and CD38. Materials and Methods: A total of 237 lymphoma cases were selected and examined within six tissue microarray paraffin blocks. Immunohistochemistry was performed using antibodies against CD117, IRF4/MUM1 and CD38. Results: CD117 and IRF4/MUM1 immunoreactivity were seen in a subset of high-grade and low-grade B-cell lymphomas, as well as T-cell lymphomas and classical type Hodgkin´s lymphomas. CD38 positivity was only detected in 1% of diffuse large B-cell lymphoma and 66% of precursor B-lymphoblastic lymphoma, in addition to myeloma cases. CD117 expression was not correlated with IRF4/MUM1 expression (P > 0.05). Two of three CD38- positive cases were positive for CD117. Conclusions: These results suggest that CD117 expression can be seen in a subset of T- or B- cell lymphoid neoplasms and plasma cell myelomas. It seems that there is no relation between the expression of CD117 and plasma cell differentiation markers in lymphomas.


CD117 expression, lymphoma, CD38 reactivity, plasma cell differentiation, IRF4/MUM1 expression

First Page


Last Page